Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer
Author:
Affiliation:
1. Discipline of Physiology; Adelaide Medical School, University of Adelaide; Australia
2. Division of Health Sciences; University of South Australia
Funder
Pfizer Australia
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference44 articles.
1. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck;Abdul Razak;Ann Oncol,2013
2. Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology;Dietrich;Hippokratia,2012
3. Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer;Sebille;Curr Opin Support Palliat Care,2016
4. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042);Kim;Lung Cancer,2017
5. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2positive breast cancer: an NSABP Foundation Research Program phase I study;Jankowitz;Cancer Chemother Pharmacol,2013
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in HER2‐positive breast cancer—A pilot study;Physiological Reports;2024-08
2. Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors;Heliyon;2024-03
3. Lapatinib-induced ErbB1 Inhibition Modulates Caco-2 Intestinal Permeability Through Tight Junction Alteration;2023-11-03
4. Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats;Neoplasia;2023-09
5. Rodent models for anticancer toxicity studies: Contributions to drug development and future perspectives;Drug Discovery Today;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3